Skip to content
  • Investors
  • News & Events
  • Contact Us
Rigel Pharmaceuticals
  • Who We Are
  • Pipeline
  • Products
  • Join Our Team
  • Investors
  • News
  • Contact Us
Rigel Pharmaceuticals
  • Who We Are
  • Pipeline
  • Products
  • Join The Team
  • Investors
  • News
  • Contact Us
Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Stock Quote
    • Charting
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts

Rigel Announces First Quarter 2018 Financial Results and Provides Company Update

May 01, 2018 4:01pm EDT

TAVALISSEā„¢ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo

Apr 30, 2018 7:30am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results

Apr 24, 2018 7:30am EDT

Rigel Announces Pricing Of Public Offering Of Common Stock

Apr 19, 2018 7:31pm EDT

Rigel Announces Proposed Public Offering Of Common Stock

Apr 18, 2018 4:34pm EDT

Rigel Announces FDA Approval of TAVALISSEā„¢ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients

Apr 17, 2018 4:51pm EDT

Rigel Makes Statement Regarding Website Error

Apr 12, 2018 3:57pm EDT

Rigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy

Apr 03, 2018 7:00am EDT

Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update

Mar 06, 2018 4:01pm EST

Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America

Mar 01, 2018 7:30am EST
RSS
  • Prev
    • 1...
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • ...31
    Next
    • Email Alerts
    • Tear Sheet
    • RSS News Feed
    • Terms of Use
    • Privacy Policy

    © 2021 Rigel Pharmaceuticals, Inc. All rights reserved.
    TAVALISSE and the Rigel arc logo are trademarks of Rigel Pharmaceuticals, Inc.
    TAVA_ITP-19277

    • facebook
    • twitter
    • linkedin
    © 2021 Rigel Pharmaceuticals • Powered by GeneratePress